VERNON, BC, Nov. 23, 2022 /CNW/ - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) ("Doseology" or the "Company"), a life sciences company focused on mental health and wellness, is pleased to announce that its line of functional mushroom supplements is launching in 48 Sobeys stores across Canada.
The placement includes 32 locations under the Sobeys banner and 16 locations under the Safeway banner, which is a subsidiary of Sobeys. Customers can find the full Doseology product line in the Rachelle Béry wellness boutique section of Sobeys and Safeway.
"Adding Sobeys to our distribution network is a significant accomplishment, as Sobeys is the second largest supermarket chain in Canada. We are very excited about this placement, as it approximately doubles our retail footprint. I am proud of the work that our dedicated team has undertaken to expand the distribution of our brand across Canada," said Doseology CEO Ralph Olson.
For sales inquiries submit an application at: doseology.com
On Behalf of Doseology Sciences Inc.
Chief Executive Officer
Sobeys Inc. (www.sobeys.com) is proudly Canadian, with more than 115 years of experience in the food retail business. As one of only two national grocery retailers in Canada, Sobeys serves the food shopping needs of Canadians with approximately 1,500 stores in all 10 provinces under retail banners that include Sobeys, Safeway, IGA, Foodland, FreshCo, Thrifty Foods and Lawtons Drugs. Sobeys is a wholly owned subsidiary of Empire Company Limited (TSX: EMP.A).
About Rachelle Béry
Rachelle Béry (www.rachellebery.ca) is a Canadian natural products grocery store that focuses on providing customers with the best wellness products possible. Since their opening in Quebec 35 years ago, they now have 10 stores and over 80 wellness boutique sections in supermarkets all over Canada. Rachelle Béry is owned by Sobeys Inc.
Doseology Sciences Inc. is building a progressive brand focused on mental health and wellness through cultivation, extraction and innovative nutraceutical and pharmaceutical products. Doseology aims to make a meaningful impact on the mental health pandemic by utilizing and developing functional fungi and plant-derived drugs. With a vertically integrated approach, Doseology intends to process and distribute products at its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high-quality production. Doseology's medicinal mushroom products, including tinctures, powders and supplements, are available on doseology.com.
This press release contains statements that constitute "forward‐looking information" within the meaning of applicable securities laws. Forward‐looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR.
No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company's securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Doseology Sciences Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/23/c5883.html
Investor Relations: email@example.com; General Inquiries: firstname.lastname@example.org, Telephone: 236-349-0064, Website: doseology.com